A common signaling cascade may underlie " addiction " to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell, pp.425-460, 2006. ,
EGFR-mutated oncogene-addicted nonsmall cell lung cancer: Current trends and future prospects, Cancer Treat Rev, 2012. ,
DOI : 10.1016/j.ctrv.2011.10.003
ALK in Lung Cancer: Past, Present, and Future, J Clin Oncol Mar, vol.1031, issue.8, pp.1105-1116, 2013. ,
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia, New England Journal of Medicine, vol.346, issue.9, pp.645-52, 2002. ,
DOI : 10.1056/NEJMoa011573
Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-155, 2005. ,
DOI : 10.1056/NEJMoa050753
Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009. ,
DOI : 10.1056/NEJMoa0810699
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
-Positive Lung Cancer, New England Journal of Medicine, vol.371, issue.23, pp.2167-77, 2014. ,
DOI : 10.1056/NEJMoa1408440
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER), The Lancet Oncology, vol.15, issue.3, pp.267-74, 2014. ,
DOI : 10.1016/S1470-2045(13)70611-9
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discovery, vol.7, issue.6, pp.586-95, 2017. ,
DOI : 10.1158/2159-8290.CD-16-1396
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, pp.open-label ,
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer, Journal of Clinical Oncology, vol.31, issue.31, pp.3987-96, 2013. ,
DOI : 10.1200/JCO.2012.45.2029
EGFR Mutation and Resistance of Non?Small-Cell Lung Cancer to Gefitinib, N Engl J Med Feb, vol.24352, issue.8, pp.786-92, 2005. ,
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay, Clinical Cancer Research, vol.17, issue.5, pp.1169-80, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-2277
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors, Science Translational Medicine, vol.105, issue.34, pp.75-101, 2011. ,
DOI : 10.1073/pnas.0803217105
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers, Clinical Cancer Research, vol.19, issue.8, pp.2240-2247, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2246
AZD9291 in EGFR Inhibitor???Resistant Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.18, pp.1689-99, 2015. ,
DOI : 10.1056/NEJMoa1411817
T790M???Positive Lung Cancer, New England Journal of Medicine, vol.376, issue.7, pp.629-669, 2017. ,
DOI : 10.1056/NEJMoa1612674
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non???small cell lung cancer harboring EGFR T790M, Nature Medicine, vol.21, issue.6, pp.560-562, 2015. ,
DOI : 10.1158/0008-5472.CAN-07-1885
URL : http://europepmc.org/articles/pmc4771182?pdf=render
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK, Proceedings of the National Academy of Sciences, vol.102, issue.21, pp.7535-7575, 2011. ,
DOI : 10.1073/pnas.0502860102
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers, Science Translational Medicine, vol.67, issue.24, pp.120-137, 2012. ,
DOI : 10.1158/0008-5472.CAN-07-1885
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, pp.1039-1082, 2007. ,
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proceedings of the National Academy of Sciences, vol.11, issue.6, pp.20932-20939, 2007. ,
DOI : 10.1128/MCB.11.6.2962
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res, pp.2895-2904, 2008. ,
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer. Sci Signal, pp.6-6, 2013. ,
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer, New England Journal of Medicine, vol.355, issue.26, pp.2733-2776, 2006. ,
DOI : 10.1056/NEJMoa064320
Resistance to BRAF Inhibition in Melanomas, New England Journal of Medicine, vol.364, issue.8, pp.772-776, 2011. ,
DOI : 10.1056/NEJMcibr1013704
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discov, pp.94-109, 2014. ,
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39 ,
DOI : 10.1056/NEJMoa1412690
URL : http://www.zora.uzh.ch/id/eprint/107163/1/Robert%20C%20et%20al.%20-%20N%20Engl%20J%20Med%202014.pdf
-Mutated Melanoma, New England Journal of Medicine, vol.371, issue.20, pp.1867-76, 2014. ,
DOI : 10.1056/NEJMoa1408868
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nature Medicine, vol.27, issue.6, pp.682-690, 2014. ,
DOI : 10.1093/bioinformatics/btt085
Oncologist Use and Perception of Large Panel Next Generation Tumor Sequencing]; Available from: https, Ann Oncol [Internet], 2017. ,
Integrative clinical genomics of metastatic cancer, Nature, vol.12, issue.7667, pp.297-303, 2017. ,
DOI : 10.1038/nmeth.3412
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors, New England Journal of Medicine, vol.363, issue.18, pp.1734-1743, 2010. ,
DOI : 10.1056/NEJMoa1007478
Resistance Mutation L1198F, New England Journal of Medicine, vol.374, issue.1, pp.54-61, 2016. ,
DOI : 10.1056/NEJMoa1508887
URL : http://europepmc.org/articles/pmc4773904?pdf=render
First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation, Clinical Lung Cancer, vol.16, issue.6, pp.259-61, 2015. ,
DOI : 10.1016/j.cllc.2015.06.002
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients, Annals of Oncology, vol.31, issue.10, pp.2073-2081, 2015. ,
DOI : 10.1158/0008-5472.CAN-14-3167
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors, Clinical Cancer Research, vol.22, issue.19, pp.4837-4884, 2016. ,
DOI : 10.1158/1078-0432.CCR-15-1915
Dual MET and ERBB inhibition overcomes intra-tumor plasticity in osimertinib resistant advanced non-small cell lung cancer (NSCLC) Ann Oncol [Internet], 2017. ,
DOI : 10.1093/annonc/mdx396
URL : https://academic.oup.com/annonc/article-pdf/28/10/2451/23066064/mdx396.pdf
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma, Molecular Cancer Therapeutics, vol.15, issue.10, pp.2521-2530, 2016. ,
DOI : 10.1158/1535-7163.MCT-16-0258
URL : http://europepmc.org/articles/pmc5289739?pdf=render
Registry, Journal of Clinical Oncology, vol.35, issue.13, pp.1403-1413, 2017. ,
DOI : 10.1200/JCO.2016.70.9352
Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.5, pp.811-820, 2013. ,
DOI : 10.1210/jc.2012-2672
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors, Cancer Discovery, vol.5, issue.8, pp.850-859, 2015. ,
DOI : 10.1158/2159-8290.CD-15-0285
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discov, pp.842-851, 2015. ,
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib, Investigational New Drugs, vol.5, issue.1, pp.397-405 ,
DOI : 10.1016/j.cllc.2015.01.009
Efficacy and safety of crizotinib in patients with advanced c-METamplified non-small cell lung cancer (NSCLC), J Clin Oncol, vol.32, pp.8001-8001, 2014. ,
MET Mutation Associated with Responsiveness to Crizotinib, Journal of Thoracic Oncology, vol.10, issue.5, pp.29-31 ,
DOI : 10.1097/JTO.0000000000000478
URL : https://doi.org/10.1097/jto.0000000000000478
Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor, Journal of Thoracic Oncology, vol.11, issue.2, pp.21-24, 2016. ,
DOI : 10.1016/j.jtho.2015.08.001
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers, Clinical Cancer Research, vol.22, issue.24, pp.5983-91, 2016. ,
DOI : 10.1158/1078-0432.CCR-16-0917
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer. Clin Cancer Res, pp.4570-4579, 2012. ,
DOI : 10.1158/1078-0432.ccr-12-0550
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/17/4570.full.pdf
RET, ROS1 and ALK fusions in lung cancer, Nature Medicine, vol.344, issue.3, pp.378-81, 2012. ,
DOI : 10.1158/0008-5472.CAN-08-2014
Rearrangements Define a Unique Molecular Class of Lung Cancers, Journal of Clinical Oncology, vol.30, issue.8, pp.863-70, 2012. ,
DOI : 10.1200/JCO.2011.35.6345
-Rearranged Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.371, issue.21, pp.1963-71, 2014. ,
DOI : 10.1056/NEJMoa1406766
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer, Clinical Cancer Research, vol.22, issue.10, pp.2351-2359, 2016. ,
DOI : 10.1158/1078-0432.CCR-15-2013
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res, pp.259-67, 2016. ,
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors, Annals of Oncology, vol.3, issue.3, pp.552-63, 2014. ,
DOI : 10.1158/2159-8290.CD-12-0362
Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer. Cancer Discov, pp.1058-71, 2013. ,
DOI : 10.1158/2159-8290.cd-12-0569
URL : http://cancerdiscovery.aacrjournals.org/content/candisc/3/9/1058.full.pdf
Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-54, 2002. ,
DOI : 10.1016/S0960-9822(97)70094-0
Mutations, Journal of Clinical Oncology, vol.29, issue.15, pp.2046-51, 2011. ,
DOI : 10.1200/JCO.2010.33.1280
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.16, pp.4532-4572, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0657
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, pp.1415-1441, 2016. ,
DOI : 10.1016/S0140-6736(16)00004-0
Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial, The Lancet Oncology, vol.17, issue.7, pp.984-93, 2016. ,
DOI : 10.1016/S1470-2045(16)30146-2
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clin Cancer Res, pp.5562-71, 2012. ,
DOI : 10.1158/1078-0432.ccr-12-1773
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/20/5562.full.pdf
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proceedings of the National Academy of Sciences, vol.60, issue.Pt 8, pp.2070-2075, 2008. ,
DOI : 10.1107/S0907444904011679
LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non???Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both, Journal of Clinical Oncology, vol.31, issue.27, pp.3335-3376, 2013. ,
DOI : 10.1200/JCO.2012.45.0981
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial, Annals of Oncology, vol.32, issue.(Suppl. 15), pp.417-440, 2016. ,
DOI : 10.1158/2159-8290.CD-14-0326
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov, pp.1046-61, 2014. ,
The cellular origins of drug resistance in cancer, Nature Medicine, vol.22, issue.3, pp.232-236, 2016. ,
DOI : 10.1038/nm.3854
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nature Medicine, vol.22, issue.3, pp.262-271 ,
DOI : 10.1038/ng1180
URL : http://www.nature.com/nm/journal/v22/n3/pdf/nm.4040.pdf
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells, Nature Communications, vol.27, p.10690 ,
DOI : 10.1093/bioinformatics/btr462
URL : http://www.nature.com/articles/ncomms10690.pdf
Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor, JAMA Oncology, vol.1, issue.7, p.982, 2015. ,
DOI : 10.1001/jamaoncol.2015.1066
URL : http://oncology.jamanetwork.com/data/journals/oncology/934521/cld150006.pdf
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies, Clinical Cancer Research, vol.21, issue.17, pp.3924-3957, 2015. ,
DOI : 10.1158/1078-0432.CCR-15-0560
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options, ESMO Open, vol.1, issue.4, p.81, 2016. ,
DOI : 10.1136/esmoopen-2016-000081
-Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.377, issue.9, 2017. ,
DOI : 10.1056/NEJMoa1704795
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer. Cancer Discov, pp.662-73, 2014. ,
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models, Cancer Cell, vol.28, issue.1, pp.70-81 ,
DOI : 10.1016/j.ccell.2015.05.010
URL : https://doi.org/10.1016/j.ccell.2015.05.010
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance, Science Translational Medicine, vol.3, issue.75, pp.120-122 ,
DOI : 10.1126/scitranslmed.3002003
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.19, issue.15, pp.4273-81, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0318
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy, Cancer Science, vol.4, issue.9, pp.1933-1941, 2010. ,
DOI : 10.1038/nrc1300
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2010.01629.x/pdf
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell, pp.77-88, 2010. ,
Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis, p.241, 2016. ,
-Amplified Lung Cancer, Clinical Cancer Research, vol.23, issue.18, 2017. ,
DOI : 10.1158/1078-0432.CCR-17-0478
Mutation, Cancer Discovery, vol.2, issue.10, pp.922-955, 2012. ,
DOI : 10.1158/2159-8290.CD-12-0108
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, Journal of Clinical Investigation, vol.116, issue.10, pp.2695-706, 2006. ,
DOI : 10.1172/JCI28656DS1
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors, Cancer Research, vol.71, issue.18, pp.6051-60, 2011. ,
DOI : 10.1158/0008-5472.CAN-11-1340
URL : http://cancerres.aacrjournals.org/content/canres/71/18/6051.full.pdf
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1, Proceedings of the National Academy of Sciences, vol.3, issue.1-2, pp.2127-2160, 2012. ,
DOI : 10.1242/dmm.003681
Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discov, pp.606-625, 2014. ,
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations, Cell, vol.141, issue.1, pp.69-80, 2010. ,
DOI : 10.1016/j.cell.2010.02.027
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway, Cancer Research, vol.73, issue.2, pp.834-877, 2013. ,
DOI : 10.1158/0008-5472.CAN-12-2066
Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC, Molecular Cancer Research, vol.11, issue.7, pp.759-67, 2013. ,
DOI : 10.1158/1541-7786.MCR-12-0652
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer, Nature Genetics, vol.88, issue.8, pp.852-60, 2012. ,
DOI : 10.2353/jmoldx.2010.090140
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398, Molecular Cancer Therapeutics, vol.16, issue.4, pp.614-638 ,
DOI : 10.1158/1535-7163.MCT-15-1010
URL : http://mct.aacrjournals.org/content/molcanther/16/4/614.full.pdf
Epithelial-Mesenchymal Transitions in Development and Disease, Cell, vol.139, issue.5, pp.871-90, 2009. ,
DOI : 10.1016/j.cell.2009.11.007
URL : https://doi.org/10.1016/j.cell.2009.11.007
Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non???Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition, Cancer Research, vol.65, issue.20, pp.9455-62, 2005. ,
DOI : 10.1158/0008-5472.CAN-05-1058
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients, Clinical Cancer Research, vol.11, issue.24, pp.8686-98, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-1492
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line, Lung Cancer, vol.63, issue.2, pp.219-245, 2009. ,
DOI : 10.1016/j.lungcan.2008.05.017
Epithelial???mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells, Gastric Cancer, vol.6, issue.7, pp.53-62, 2016. ,
DOI : 10.1097/JTO.0b013e318216ee52
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions, Clinical & Experimental Metastasis, vol.6, issue.5, pp.685-93, 2008. ,
DOI : 10.1111/j.1432-0436.2006.00075.x
URL : https://link.springer.com/content/pdf/10.1007%2Fs10585-007-9121-7.pdf
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by 6 ,
DOI : 10.1038/onc.2010.509
URL : http://www.nature.com/onc/journal/v30/n12/pdf/onc2010509a.pdf
Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung, Clinical Lung Cancer, vol.11, issue.5, pp.1-4, 2010. ,
DOI : 10.3816/CLC.2010.n.046
BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors. Cancer Discov, pp.352-65, 2011. ,
Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia, European Journal of Cancer, vol.45, issue.10, pp.1877-89, 2009. ,
DOI : 10.1016/j.ejca.2009.04.005
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer, Nature Medicine, vol.63, issue.4, pp.521-529, 2012. ,
DOI : 10.1038/nature03556
50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond, Nature Reviews Molecular Cell Biology, vol.18, issue.4, pp.258-64, 2014. ,
DOI : 10.1128/MCB.01245-07
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells, Oncol Rep, 2013. ,
Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line, International Journal of Oncology, vol.46, issue.1, 2014. ,
DOI : 10.3892/ijo.2014.2733
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma, New England Journal of Medicine, vol.375, issue.9, pp.819-848, 2016. ,
DOI : 10.1056/NEJMoa1604958
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy, Cell, vol.168, issue.4, pp.707-730, 2017. ,
DOI : 10.1016/j.cell.2017.01.017
URL : https://cloudfront.escholarship.org/dist/prd/content/qt5st231s3/qt5st231s3.pdf
Abstract 1011: RNAseq analysis obtained from on-purpose tumor biopsies of patients in the MATCH-R trial allows the identification of potential mechanisms of acquired resistance to PD(L)1 therapies, Cancer Research, vol.77, issue.13 Supplement, pp.1011-1011, 2013. ,
DOI : 10.1158/1538-7445.AM2017-1011
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, issue.1, pp.35-44, 2016. ,
DOI : 10.1016/j.cell.2016.02.065
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade, Cancer Discovery, vol.6, issue.8, pp.827-864, 2016. ,
DOI : 10.1158/2159-8290.CD-15-1545
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res, pp.1920-1928, 2017. ,
Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate, Clin Cancer Res, p.3133, 2016. ,